Go online to PeerView.com/VHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of improved understanding of the genetic mechanisms underlying solid tumors, PARP inhibitors are now validated treatments for patients with ovarian, prostate, breast, and pancreatic cancers. Targeting DNA damage response (DDR) mutations, which have an important role in tumorigenesis, PARP inhibitors are now being studied in other cancers, as well as in combination with immunotherapies and other agents. Approvals of PARP inhibitors have, in some cases, brought with them approvals of companion diagnostics or complementary diagnostic tests. Join a panel of oncology experts for a PeerView MasterClass providing in-depth education on PARP inhibitors, including the rationale for their use, the latest efficacy and safety data in a variety of tumor types, and investigational uses of these agents. Didactic presentations will be supplemented with a practicum session featuring guidance and clinical perspectives on diagnostic testing, dosing considerations, managing AEs associated with PARP inhibitors, and selecting patients for clinical trial enrollment. Upon completion of this accredited CE activity, participants should be better able to: Discuss the rationale for use and the expanding role of PARP inhibitors in the treatment of different cancers, including malignancies of the ovaries, prostate, breast, and pancreas, Describe the efficacy and safety profiles of PARP inhibitors and the role of diagnostic testing in guiding patient selection across a range of cancers, Implement appropriate strategies for integrating PARP inhibitors, either through approved indications or clinical trial enrollment, into treatment plans for patients with cancer, Formulate strategies to prevent and/or manage PARP inhibitor–associated AEs.